Amneal Pharmaceuticals (AMRX) Change in Accured Expenses (2017 - 2026)

Amneal Pharmaceuticals' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$124.6 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 10.61% year-over-year to -$124.6 million; the TTM figure through Mar 2026 stood at $9.4 million (down 84.47% YoY), while the FY2025 annual figure was $21.3 million, down 90.93% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$124.6 million, down from $18.6 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $322.7 million in Q2 2022, with the low at -$150.5 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $33.1 million (2023), against an average of $8.6 million.
• Peak annual rise in Change in Accured Expenses reached 1905.87% in 2022, while the deepest fall reached 828.86% in 2022.
• Amneal Pharmaceuticals' Change in Accured Expenses stood at -$55.9 million in 2022, then surged by 64.63% to -$19.8 million in 2023, then surged by 435.29% to $66.3 million in 2024, then plunged by 71.96% to $18.6 million in 2025, then tumbled by 770.6% to -$124.6 million in 2026.
• Business Quant data shows AMRX's Change in Accured Expenses at -$124.6 million in Q1 2026, $18.6 million in Q4 2025, and $69.7 million in Q3 2025.